Victory! Colombian Government Cuts Price of Abbott's Lifesaving AIDS Drug Kaletra...

Victory! Colombian Government Cuts Price of Abbott's Lifesaving AIDS Drug
Kaletra 55%, Says AHF

Advocates Claim Victory as Government Cuts & Freezes Price at $1,067 USD for
Public Institutions and $1,591 USD for Hospitals, Clinics & Private
Sector--55% Less than Abbott's Previous Colombian Price

Since January, Colombian, Mexican & US AIDS Advocates Protested Steep Price of
Drug in Developing Countries; Compulsory License in Colombia Would Further Cut
Price to Less Than $600/Patient/Yearly

MEXICO CITY, May 11 /PRNewswire-USNewswire/ -- Colombian and international
AIDS advocates and activists claimed victory today after the government of
Colombia announced that it will cut the price of Abbott Laboratories'
lifesaving AIDS drug, Kaletra to $1,067 USD for the public sector hospitals
and clinics and $1,591 USD for the private sector. Government officials had
asked the Chicago-based pharmaceutical giant to voluntarily lower the price;
however, the company refused. As a result, Colombia invoked its power to cut
and freeze the price of the key AIDS drug. The cut represents a roughly 55%
price reduction in Colombia, where Abbott previously charged the private
sector approximately $3,500 USD per patient yearly for the drug.

"Colombia's action today to cut the price for Abbott's Kaletra is of major
importance, a move that will undoubtedly help save many, many lives by making
lifesaving AIDS drug regimens more widely available in the country. We salute
the tireless AIDS activists and advocates on the ground who raised awareness
through protests and media outreach that helped keep this issue in the
forefront. I am not aware of another instance in which the government of a
country came in and cut and put a price ceiling on an AIDS drug." said Clint
Trout, MPH "However while this is an important victory, we call on the
Colombian government to accede to local activists demands to issue a
compulsory license for Kaletra, which would allow Colombia to purchase the
medication at less than $600 per patient per year and would save many
additional lives."

In January of this year, as part of an ongoing multinational campaign to lower
drug prices and improve access to lifesaving AIDS treatments globally, AIDS
advocates from three countries--Colombia, Mexico and the United States--held
simultaneous protests in the three countries. The protests targeted
Chicago-based Abbott Laboratories over the pricing of Kaletra, which can be a
key component of lifesaving AIDS drug treatment regimens, particularly as part
of what are known as 'second-line' treatments and salvage therapy. The
advocates vowed to seek compulsory licenses in Mexico if Abbott did not reduce
prices for the drug and have officially requested a compulsory license in
Colombia. The Colombian Government is expected to rule on the compulsory
license this week.

"In our protests in the three countries in January, we pressed Abbott to
reduce the price of Kaletra in Colombia and Mexico," said Michael Weinstein,
AIDS Healthcare Foundation President. "The lives of people living with--and
dying from--HIV/AIDS in Colombia and Mexico are just as important as those of
people living with AIDS here in the United States. In March, we claimed
partial victory when Abbott cut the price of Kaletra by twenty percent in
Mexico. Today's action by the Colombian government helps bring about an end to
Abbott's price-gouging policies that shamefully continue to place profits
ahead of saving lives. We call on the Colombian government to use these
savings to improve treatment and care for persons living with HIV/AIDS in
Colombia."

In late March, a coalition of AIDS activists known as the Coalicion de
Activistas por el Acceso Universal spearheaded by AIDS Healthcare Foundation
(AHF), which operates four free treatment clinics in Mexico (Puerto Vallarta,
Cancun, Tuxtla Gutierrez and Pachuca), declared victory in its campaign to
lower drug prices and improve access to lifesaving AIDS treatments in Mexico.
As a result of that coalition's prolonged, multinational campaign to raise
awareness about the high price charged by Abbott Laboratories Inc. for its key
AIDS drug, Kaletra in Mexico, the company cut its price by twenty
percent--from $4688.00 pesos MXN per patient per month to $3750.40 MXN. The
new lower price was published for the first time in med-March on the website
of CENSIDA, Mexico's National Center for the Prevention and Control of
HIV/AIDS.
The Colombian organizations: Mesa de Organizaciones con Trabajo en VIH/SIDA,
the Red Colombiana de Personas Viviendo con VIH o con SIDA, Mission Salud, and
IFARMA requested a compulsory license for Kaletra from the Ministry of
Commerce in 2008 and have been leading the push for the compulsory license and
lower prices with assistance from AHF and Washington-based Essential Action.
The Ministry of Commerce has requested the Ministry of Social Protection to
rule whether or not Kaletra is a medication "in the public interest." This
ruling is expected this week.
Abbott has long been the target of multinational protests and legal actions
over the pricing of its AIDS drugs including Kaletra and Norvir. Over the past
several years as many of Abbott's industry peers have significantly lowered
the prices of their own lifesaving AIDS medicines on their own volition and in
response to worldwide humanitarian need, Abbott has remained steadfast in its
refusal to do so, or it has countered advocates' and governments' demands with
only modest price reductions.

According to the website, www.aidsmeds.com, "Kaletra, a protease inhibitor
(sold under the brand name Aluvia in some parts of the world), is actually two
drugs combined into a single capsule: lopinavir and low doses of ritonavir
(Norvir), another protease inhibitor manufactured by Abbott Laboratories. This
is because ritonavir increases the amount of lopinavir in the blood, thus
making it more effective against HIV."

Kaletra in Colombia

-- Colombia is a lower-middle income country with an average income per
capita of $2,600 per year.(1) The country has one of the most serious
HIV/AIDS problems in the region: 170,000 people living with AIDS and a
rapidly rising HIV prevalence (currently 0.7%).(2) An average of
10,000
people each year die from AIDS in the country.(3)

-- Colombia is unable to provide antiretroviral therapy to those who need
it. UNAIDS estimates that 33,000 people with AIDS who need ARV
therapy
now (62% of the total) are not currently accessing it.(4)
Colombia's government is spending $70 million each year for AIDS
drugs (all national funding).(5)

-- Abbott promotes Colombia as receiving a preferred price of $1,000 per
patient per year for lower-middle income countries on its website.(6)
However, in reality Abbott charged Colombia $8,400 per patient per
year
up through mid-2007.(7)(8) Abbott is currently charging $3,500 in
Colombia.(9)

-- Abbott uses unorthodox and unethical marketing strategies in Colombia
to
promote Kaletra. This includes offering classes, dinners, and trips
to
patients on Kaletra.(10) As a result, Kaletra is the 2nd-most widely
prescribed AIDS medicine in Colombia, highly unusual for a 2nd-line
medication. Kaletra accounts for 1/3 of Colombia's AIDS drug
costs.(11)

-- On April 7, 2008, the Mesa de Organizacions con Trabajo en VIH/SIDA
and
the Red Colombiana de Personas Viviendo con VIH o con SIDA requested
an
open license on Kaletra. The local Colombian generics industry has
the
capacity to manufacture Kaletra at much lower costs AND Colombia has
an
agreement with the Clinton Foundation through which it could get a
generic version of Kaletra for approximately $600 per patient per
year.(12) Abbott did not respond.

About AHF

AIDS Healthcare Foundation (AHF) is the nation's largest non-profit HIV/AIDS
healthcare provider. AHF currently provides medical care and/or services to
more than 100,000 individuals in 21 countries worldwide in the US, Africa,
Latin America/Caribbean and Asia. Additional information is available at
www.aidshealth.org

(1) United Nations Development Program (www.undp.org)
(2) Resumen de Situacion de la Epidemia por VIH/SIDA en Colombia. (Dec 2007)
Ministerio de Proteccion Social, Colombia.
(3) UNAIDS http://www.unaids.org/en/CountryResponses/Countries/default.asp
(4) World Health Organization (April 2008). Universal Access Report.
(5) 2008 UNGASS Report, Colombia.
(6)
http://www.abbott.com/global/url/content/en_US/40.5.10:10/general_content/General_Content_00327.htm
(7) Garavito, L, Gomez, F. (2006) Analisis regulatorio del mercardo
institucional de medicamentos antiretrovirales en Colombia.
(8) Personal Communication with Abbott Laboratories in Colombia.
(9) Local price survey.
(10) AHF can provide 1st hand accounts on request.
(11) Garavito, L, Gomez, F. (2006) Analisis regulatorio del mercardo
institucional de medicamentos antiretrovirales en Colombia.
(12) Clinton HIV/AIDS Initiative. www.clintonfoundation.org

SOURCE AIDS Healthcare Foundation

MEXICO, Clint Trout MA MPH, MX Mobile +52(1)55.19.19.17.73, MX Work
+52.55.52.64.72.95, ctrout@bu.edu; UNITED STATES, Ged Kenslea, Communications
Director, AIDS Healthcare Foundation, 6255, West Sunset Boulevard, Los
Angeles, CA, USA, +1-323-860-5225 [work], +1-323-791-5526 [mobile],
gedk@aidshealth.org; or COLOMBIA, Luz Marina Umbral (Spanish), +57 55 315 323
5765, Francisco Rossi, PhD, +57 (1) 232 6244, +57 (314) 468-8791 cell,
licencia.obligatoria.colombia@gmail.com